Lingvay I, Bergenheim SJ, Buse JB, et al. Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol 2025; 13: 935–48—In this Article, the total triglycerides concentration in table 1 has been corrected to 1·9 mmol/L; table 2 has been corrected to show that the supportive secondary endpoint of BMI (kg/m2) was assessed in 291 patients in the semaglutide 7·2 mg group; and the exploratory endpoint of the proportion of patients with a decrease in lipid-lowering medication was assessed in 0 of 103 participants in the semaglutide 2·4 mg group.
The Lancet Diabetes & Endocrinology published a clinical update in Research Highlights on 31 Mar 2026. The item focuses on Correction to Lancet Diabetes Endocrinol 2025; 13: 935–48. Open the detail page to review the full original feed content.